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Purpose: Smart medication adherence monitoring devices can provide objective and granular
drug utilization data and help patients engaging with their treatment. In this proof-of-concept
study, the acceptability and technical robustness of a novel smart pill bottle prototype (SPBP)
were assessed in order to allow further optimization.
Methods: The SPBP is an app-controlled automatic dispense system, capturing real-time
data on a web-based platform, which sends text reminders and measures storage conditions.
A heterogeneous group of ten volunteers was asked to dispense placebo capsules with the
SPBP and to follow a predefined dosing schedule for a trial period of 2 weeks. Afterwards,
a questionnaire was filled out during a short interview. Primary outcome was dispense
adherence as measured by the bottle. Other study outcomes included system acceptability
(System Usability Scale [SUS]), self-reported adherence (MARS) and technical robustness
of the bottle’s mechanics (electronic pill dispenser) and sensors (bottle temperature).
Results: The overall dispense adherence rate as measured by the SPBP was 88%. All
participants completed the study and four participants had an adherence rate of 100% during
the study. The dispense adherence rates corresponded well with participants’ self-reported
adherence with an average MARS total score of 23.6 (out of 25). Participants judged the
system easy to use, with a mean SUS score of 79.3 (range: 57.5–97.5). The overall mean
temperature difference between the bottle sensor and calibrated external sensor was −0.82°C
(range: −1.37°C to −0.21°C).
Conclusion: The SPBP was well accepted and this study provides data for further optimiza-
tion and follow-up studies. Smart adherence technologies such as these may change the way
healthcare professionals, trialists and patients manage medication adherence.
Keywords: smart device, real-time monitoring, medication management, electronic data,
medication dispenser, mobile app
Introduction
Up to half of the people taking medication for chronic conditions are non-adherent.1,2
Medication non-adherence hinders disease control and places a significant negative
burden on patients’ quality of life. Notably, the World Health Organization (WHO)
concludes that improving patients’ adherence may have a greater effect on patients’
health than any other improvement in therapy.1 Besides clinical impact, non-adherence
also has economic impact as it may lead to increased use of healthcare resources.3
Over the last decade, a wide range of promising smart devices has been developed
that can monitor medication adherence.4 Data from these smart devices provide
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information that is granular – eg more time points – than
a pill count, and more objective than patient self-report.
These data can also be complimentary to – and even help
explain – clinical and biochemical laboratory findings such
as response biomarkers and drug concentrations.5–8 Finally,
these smart devices can directly support interventions,
patient self-monitoring, and help appropriate implementation
of a prescribed medication regimen.9
The technology for medication monitoring of solid doses
by smart pill bottles (SPBs) is rapidly developing with new
options for electronics, sensors, real-time data collection, and
direct communication between patients and healthcare profes-
sionals or trialists.10 However, the currently used SPBs still
suffer from the limitation that they only measure the opening
of the bottle and not whether a dose has actually been taken out
and – if so – how many.11–13
Recently, a novel smart pill bottle prototype (SPBP), the
Elucid Pill Connect system, has been developed with the
aim of providing insights into non-adherence and support-
ing patients to better manage their medicines.14 The system
consists of a regular pill bottle equipped with an automated
dispense and reminder system that connects to a mobile app.
Within a predefined timeframe, only the prescribed number
of pills is released and at the moment of dispense the time
and temperature are logged. The SPBP has potential for
both daily practice and clinical trials. However, the usabil-
ity, reliability and acceptability need to be established first
before wide-scale implementation.
Therefore, this proof-of-concept study was designed to
test this possible new medication adherence intervention
by the means of human factor testing and product evalua-
tion in healthy volunteers. It aims to elucidate user accep-
tance and technical robustness of the first prototype of an
SPB, to ultimately inform the development of a final ver-
sion ready for scale-up.
Methods
Study Design
This proof-of-concept trial involved 10 healthy volunteers
using the SPBP with placebo capsules for 14 days between
June and July 2019. Afterwards, the SPBP was evaluated
by all subjects to understand the impact and barriers to its
use. This study was registered at the Dutch trial registry
(Trial NL7835).
Participants
The study was performed with volunteers recruited through
the UniversityMedical Center Groningen in the Netherlands.
Subjects were eligible for the trial if all of the following
criteria were met: age >18 years, own an Android or
iPhone mobile phone with operating system versions
Android ≥6.0 or IOS ≥11.4, able to operate the mobile
phone themselves and provide informed consent. There
were no exclusion criteria assessed prior to enrollment.
Exclusion criteria assessed after enrollment were the with-
drawal of informed consent and unavailability of the subject
to participate in the trial.
Twenty-one individuals were asked for their interest in
participation; 19 (90%) showed interest and were recruited
and assessed for their availability during the study period.
From this pool, 10 volunteers were randomly selected and
balanced by gender, age group, education level and smart-
phone operating platform in order to achieve a heterogeneous
group. All participants provided written consent to partici-
pate in the study.
Procedures
First, all participants were asked to attend a presentation
where they received information on the trial and a short
training on how to use the SPBP. Subsequently, all sub-
jects had two site visits. At Visit 1, they received their
SPBP connected to a temperature logger and containing
a sufficient number of placebo capsules. They also
received written information and a short explanation on
SPBP use. At Visit 2, they returned the bottles and tem-
perature loggers and completed the questionnaire and
a short interview on problems that occurred and sugges-
tions to optimize the system. During the first week of the
study, all participants were instructed to dispense one
morning dose. In the second week, all participants were
instructed to dispense a morning dose and an evening
dose. For each dose, the participants had a time frame of
6 hr to perform the dispensing. When the participants did
not dispense within the first 3 hr, an SMS reminder was
sent.
Technical Specifications of the Smart Pill Bottle
The SPBP (Elucid Pill Connect system, eLucid mHealth
Ltd, Manchester, United Kingdom) is a patented system
that allows for electronic dispenses of medication units
(tablets or capsules), registering the time, bottle temperature
and number of units that are dispensed. The smart bottle
consists of a standard white plastic pill bottle with an auto-
mated dispensing module inserted. This module is powered
by a small battery. The system is operated by a mobile phone
application, and can only be unlocked when a dose is due.
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This prevents double dosing. In case, for example, serious
side-effects occur during a clinical trial, bottles can be
centrally locked from a distance. Data are sent real-time to
a dedicated platform, which can be viewed by healthcare
professionals or trialists, see Figure 1. Via the app, users
have insight in their dosing schedule and get SMS reminders
when their dose is due or when they are about to forget their
medication. For the purpose of the trial, bottles were made
transparent instead of white so that the dispensing mechan-
ism could be easily observed.
Questionnaire
All participants completed the questionnaire that included the
System Usability Scale (SUS),15,16 additional satisfaction
questions and the Medication Adherence Report Scale
(MARS).17 The questionnaire incorporated the five-point
Likert scale where one is “always” and five is “never”. SUS
is a measure for user acceptance of a new system, where
a user rates 10 questions on topics such as the need for
support, training, and complexity of the system. The outcomes
are scored and the overall value ranges from 0 to 100, where
high scores indicate good usability. The additional satisfaction
questions were self-designed.More details can be found in the
Supplementary Materials. MARS is a scale consisting of five
topics, where a subject rates self-assessed engagement in non-
adherent behavior and where higher scores indicate higher
levels of adherence. The validated Dutch translation was used.
Temperature Validation
To validate the temperature sensor inside the SPBP (LMT85-
Q1, Texas Instruments, Dallas, Texas, United States)
a calibrated temperature data logger (Testo 174T, Testo SE
& Co. KGaA, Lenzkirch, Germany) was attached to each
SPBP. Temperature data of the internal sensor were recorded
at every dispense, whereas the external logger recorded every
5 mins. As it was assumed that environmental temperature is
quite stable, two external temperature measurements were
averaged around the time of the sensor measurement.
The mean temperature difference between the bottle
sensors and the external loggers was calculated per bottle.
Figure 1 Data transfer of the SPBP system.
Notes: Dispenses are performed through an app on the mobile phone. Time and temperature data are registered when the dose is successfully dispensed, and then loaded
to an online platform.
Dovepress Zijp et al





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
To evaluate the systematic bias of the temperature sensor,
a Bland–Altman plot was used for all measured data
points.18 In this plot, the difference between the two paired
temperature measurements (y-axis) is set out against the
average of the two measurements (x-axis). The limit of
agreement (LOA) represents 95% of the differences
between the two measurement methods (± 2 SD).
Outcomes
The primary outcome was the percentage of capsules suc-
cessfully dispensed according to the intended dosing sche-
dule. Secondary outcomes were user acceptance, measured
with the SUS, additional satisfaction questions, self-reported
adherence (MARS) and technical validation, ie correct dis-
pense and logging of dispense data, sending of reminders,
central locking at distance and temperature validity.
Outcomes were reported with descriptive statistics
where appropriate.
Ethics
On the basis of the study protocol, the Medical Ethics
Review Board of the University Medical Center Groningen
(METc UMCG, number: 2019/332) exempted this study
from the Medical Research Involving Human Subjects Act.
This research followed the declaration of Helsinki and the
General Data Protection Regulation. No clinical data were
collected or used during this study and there were no changes
to subjects’ regular care routines.
Results
Participants
The characteristics of the 10 study participants are shown in
Table 1. Participants had equal gender balance and varied in
age group, education level, smartphone platform and
experience with following a medication schedule (regarded
as chronic medication use). All participants completed both
study visits.
Dispensing and Adherence
During the study, a total of 168 capsules out of 190 were
successfully dispensed, which implicates an overall dis-
pense adherence of 88% to the intended dosing schedule.
Four participants had an adherence rate of 100% during
the study. A total of 22 doses were missed by six partici-
pants. Of these missed doses, 12 were due to human error
(eg forgot the bottle at home) and 10 were missed because
of a product design problem (with nine of those occurring
in the same bottle, further discussed in the technical eva-
luation). The participants had a high self-reported adher-
ence with an average MARS total score of 23.6 out of 25;
the participants’ responses are reported in Figure 2.
User Acceptance
The majority of the participants judged the system usability
acceptable, with a mean SUS score of 79.3 (range: 57.5 to
97.5). The responses of the participants to the SUS question-
naire are shown in Figure 3. In the questionnaire, most
participants (80%) thought the system was easy to use; two
participants thought that most people would need training of
which one participant needed to learn a lot before they could
get going. No participants needed the support of a technical
person. In total, 70% liked to use this system frequently.
In the additional questions, as shown in Figure 4, all but
one user found both the dispenser as the application simple to
use. However, they found it uneasy to carry the dispenser
around (30%), and handling the system was more difficult
than standard drug packaging (40%). Half of the group found
benefits from this system. Most participants (80%) were
positive towards the idea that a healthcare professional
received information about their medication intake, while
two participants marked this question as “not applicable”,
as there was no actual information shared with healthcare
professionals in this study. Being reminded by the system and
Table 1 Characteristics of the Study Participants (Total n=10)
Characteristics Participants








Academic education 4 (40%)
Higher professional education 2 (20%)




Familiar with Regular Medication Use
Yes 5 (50%)
No 5 (50%)
Note: aAccording to the Dutch education system.
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0 2 4 6 8 10
Forget to take the medication
Modify the doses
Stop taking medication during
a period
Decide to miss a dose
Take less than prescribed




Figure 2 Medication adherence report scale scores.
0 1 2 3 4 5 6 7 8 9 10
Would like to use this system frequently
The system was unnecessarily complex
The system was easy to use
Would need support of a technical person
Various functions were well-intergrated
Much inconsistency
Most people would learn to use this very quickly
Very cumbersome to use
Felt confident using the system
Needed to learn a lot before I could get going




Figure 3 System usability score for the smart pill bottle prototype.
0 1 2 3 4 5 6 7 8 9 10
The dispenser was simple to use
The dispenser was simple to carry around
The mobile application was simple to use
Dispensing is more difficult than standard packaging
I found benefits from using the Pill Connect system
It was beneficial to know my health professional received
information about my medicine
It was useful having the dispenser give me the correct
quantity
It was useful being reminded by the application
It was useful seeing my upcoming doses on the
application
I find remembering to take my medicine at the correct
time difficult
I would like help for taking my medicines on time





Figure 4 Additional questions on the smart pill bottle prototype.
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seeing upcoming doses was appreciated by 60% of the parti-
cipants. Only three of the participants reported problems with
taking their medicine at the correct time, where four liked
help for taking their medicine on time.
Technical Evaluation
All bottles’ batteries remained functional during the length
of the trial. Nine bottles were in proper condition after the
end of the study. In one bottle, the automated dispensing
mechanism got jammed due to a technical problem.
Dispensing data were correctly logged and sent to the
platform for all dispenses. All capsules that were dis-
pensed were confined to the permitted time window.
In the short interview, seven participants reported that
they encountered an error during the study. Two partici-
pants reported that not all capsules were dispensed suc-
cessfully due to an error in the dispensing mechanism.
Two participants reported a situation where a double
dose was dispensed. Other errors were easily resolved by
the participants in their next attempt by shaking the bottle
and trying to dispense again.
Furthermore, two participants reported that they got
reminders after they already performed a dispense. In
these situations, data were not rapidly synchronized but
loaded in the next dispense at most times, while the parti-
cipants were connected to Wi-Fi and to the mobile network
at the moment of dispense. Moreover, participants reported
that they did not always get their reminders when needed.
Temperature
There were 188 data points where the recorded temperature
of the SPBP sensor could be compared with the external
temperature logger data, with temperatures that ranged
from 13.1°C to 26.6°C, as shown in Figure 5. Temperature
data of Android phones were more detailed as there was one
decimal available, whereas iOS phones only recorded whole
numbers. The overall mean temperature difference was
−0.82°C, where the mean temperature difference per bottle
ranged from −1.37°C to −0.21°C. These data implicate that
the temperatures that were measured within the SPBP are
lower than the measurements of the external logger. When all
data points were combined, the mean temperature difference
between the methods was −0.78°C (SD: 0.70, LOA: -2.15,
0.58), see Figure 6.
Lock-Out
On the last day, all bottles were successfully locked. There
were no dispenses recorded during this lock-out period,
and in the short interview all participants confirmed that
no dispense was possible.
Outcomes per Adherence Type
The main method and score outcomes were stratified per
adherence type as determined by the number of dispensing
attempts that were made by the participant, as shown in
Figure 7. Participants with a 100% intended adherence
missed no capsules and regarded the system with a lower
SUS score. However, one participant still regarded them-
self as non-adherent. There was one capsule count discre-
pancy caused by a double dispense. Of the three
participants that had 90–99% dispense adherence, one
told during the interview that she did not miss a dispense
and regarded herself as adherent. All three rated the SUS
score high. All participants with a lower SPBP-measured
adherence also reported being non-adherent during both
the interview and the questionnaires.
Suggestions for Optimization
Several participants recommended to personalize the timing
of the reminders. Two participants asked for a strict time point
to receive the messages, of which one asked for an earlier
timing to fit the message into their morning schedule. One
participant wanted to set the time of the messages himself.
Another suggestion regarding reminders was to use pop-ups
in the app instead of SMS reminders. One participant sug-
gested to do more with the phone during the training and to
explain how to install sound options when reminders come in.



























































Figure 5 Comparison of temperatures that were measured simultaneously by the
sensor inside the smart pill bottle prototype (x-axis) and by the calibrated external
temperature logger (y-axis).
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reported that it works better for her just to set an alarm on her
phone (as it overrules the silence).
Therewere a few suggestions to improve the system. Two
participants suggested an option in the application where you
can look back which doses were due, or that all medication
taken is put into a graph. Moreover, one participant wanted
an emergency option, so access to the medication would be
granted when the mobile phone would crash.
Discussion
In this study, we evaluated dispense adherence rates, user
acceptance and technical robustness of a novel smart pill
bottle prototype. While both adherence and acceptability
were high, the dispense and reminder systems require
further optimization.
All participants completed the trial and were adherent
to their placebo dosing schedule, which was reflected in
the self-assessed adherence. The user acceptance was high,
as the majority of the participants saw benefits in the
system and thought it was easy to use. To increase user
acceptance, some suggestions were given to optimize the
system.
For the technical robustness, all dispensing moments


























Average of measurements (°C)
Figure 6 Bland–Altman to evaluate the bias between the measurements of the internal temperature sensor and external temperature logger.












Interview: missed ≥1 
dispense 
MARS score: low adherence
Capsule count discrepancy
Questionnaire answer: "I find







Figure 7 Association of smart pill bottle-defined dispense adherence rates (<90%, 90–99% and 100%) versus various alternative adherence indicators.
Note: A low MARS score is defined as a score of 24 or less.
Abbreviations: MARS, Medication Adherence Report Scale; SUS, System Usability Scale.
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temperature accuracy was within the accuracy range as
given by the sensor manufacturer,19 but did not reach the
expected average of ±0.4°C. In total, 95% of all measure-
ments ranged between a difference of −0.5 to 2.1°C. This
accuracy may be regarded as acceptable for less tempera-
ture-sensitive drugs, as temperature differences may still
exist between the in-and outside of the bottle. For highly
temperature-sensitive drugs, this discrepancy needs further
investigation. Furthermore, all participants were locked
out successfully at the end of the trial.
However, two issues were identified in the technical
aspects of the bottle. First, a manufacturing error for the
prototype was signaled and this has been reported to the
manufacturer. Accordingly, the manufacturer has intro-
duced a new process and quality assurance to prevent
this from happening again. Second, the double dispense
events could be attributed to the study-specific use of see-
through bottles instead of the common white bottles, as the
sensor in the dispensing mechanism was possibly saturated
with scattered infrared light.20 Indeed, both participants
that encountered this problem were outside when they
performed the dispense. The manufacturer will therefore
increase the power of the sensor and provide a secondary
block of dark plastic to the bottles.
The observed high adherence rates were significantly
higher than real-world adherence rates. Indeed, trial parti-
cipation generally improves adherence behavior. While the
general impact of being electronically monitored may be
low,13,21 this system was especially designed to improve
adherence by involving patients in their dose schedule and
sending reminders. Previously, reminders were shown to
improve adherence.22–27 According to our findings, these
reminders could be more beneficial when better timed and
personalized by end-users.
Assessment of SPBP Assets
The SPBP tested in this study records the exact time,
temperature and number of capsules that are dispensed.
Furthermore, all data could be accessed in real-time. This
could potentially improve intake data for trials as the
trialist can immediately take action and have an open
discussion with the participant based on the provided
adherence overview. However, this could also increase
the stigma of being monitored and raise privacy concerns.
Another downside is that the moving parts in the dispen-
sing mechanism have a risk of blockage and may have
a higher impact on battery durability.
An additional opportunity of this system is the tem-
perature monitoring. In clinical trials, drug storage condi-
tions are tightly regulated before giving out to the patient
to ensure product quality and drug stability.28 However,
when at home, patients may store their medication at less
suitable places, eg in a bathroom or a windowsill in the
sun, where the medication can reach high temperatures.29
As the container is air-sealed with a cap and only the
required amount is dispensed, the content will be mini-
mally exposed to humidity. Adding a sound alarm may
increase participants’ awareness when the temperature is
outside the recommended storage range. For this purpose,
the temperature should be measured continuously.
Another asset of the system is its ability to send
reminders. Text reminders have previously shown to be
a simple and effective way to increase adherence.23–27 On
the other hand, a high frequency of reminders may intro-
duce response fatigue. In this system, reminders are sent
only when this information is relevant (ie when doses are
not taken), which may even trigger the subjects to take the
medication before the reminder time.30 While in this study
these reminders were sent at a certain time point, the
system is suitable to be adjusted to user preferences.
Strengths and Limitations
Usability studies are an important step in the development
of user-friendly technologies, as they provide valuable
user feedback on needs and expectations. Strengths of
this study were that participants were randomly selected
to obtain a heterogeneous group, and the use of multiple
methods to assess adherence and satisfaction.
However, there were also some limitations, including
generalizability and sample size. As this study did not
use prescribed medication, no formal medication adher-
ence could be tested. Furthermore, the participants in this
study were on average young, healthy, and half of them
was not accustomed to a medication schedule. While the
age groups and education levels that were covered in this
study could be possible target groups for this device,
their experiences may differ from the experiences of
actual medication users, who may feel more unwell and
may use the device for a longer period. Younger partici-
pants are also in general more comfortable with new
e-technology. Whether higher age groups could benefit
from this device is not covered in this study. For parti-
cipants that do not possess or know how to operate
a smartphone, other non-smartphone-connected devices
Zijp et al Dovepress
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(MEMs, blister packs, week boxes) may be more suita-
ble to track and support adherence.
While the small sample size could be considered
a limitation, similar numbers have previously been
reported for other pilot studies on system usability.31–33
Implications for Future Research
This study gives insight in the development process of
a mobile phone-connected pill bottle, provides design
and implementation considerations and may stimulate
further research in features to improve and monitor adher-
ence. Suggested improvements from this study related to
optimization of the manufacturing process and personali-
zation of the app-based reminder system. When these
improvements to the SPBP are made, a follow-up trial
with the next SPB version is recommended, until 100%
robustness and high user satisfaction is shown.
Ultimately, application of these SPBs could be diverse.
For example in clinical trials, these pill bottles would be
suitable to assess non-adherence, but also in pharmacoki-
netic research, where knowledge of the precise time of
intake, dose and storage environment of the drug are
pivotal for estimations of exposure and explanation of
individual variability in drug response.
Conclusion
The SPBP was well accepted and this study informs
further technical optimization and follow-up studies.
Taking into account patient needs and usability is impor-
tant in the development of new technologies. The issues
that were uncovered may stimulate further research and
advancements in the smart adherence devices area.
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